Actavis to buy Warner Chilcott for US$8.5b
May 21, 2013
CONSOLIDATION in the generics
business is continuing, with the
news overnight that Actavis has
agreed to acquire Ireland-based
Warner Chilcott for US$8.5 billion.
No cash is to change hands, with
the deal to be settled by a stock
swap by the end of the year.
The newly created company, to
be called Actavis PLC, will be led by
the current Actavis management,
according to the Wall Street Journal.
Actavis said the acquisition would
see the resulting business have
about $11 billion in combined
annual revenue, and be the third
largest US specialty pharmaceutical
manufacturer, focusing on women’s
health, gastroenterology, urology
and dermatology.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 May 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 May 13